MOUNTAIN VIEW, Calif., Nov. 27 MAPPharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company willpresent at the following upcoming investor conferences on November 28th andDecember 12th, 2007 in New York City:
A live webcast of the presentations will be available on the InvestorRelations section of MAP Pharmaceuticals' website at http://www.mappharma.com.A replay will also be available within 24 hours for seven days following thepresentation.
About MAP Pharmaceuticals, Inc.
MAP Pharmaceuticals, Inc. uses proprietary inhalation technologies toenhance the therapeutic benefits and commercial attractiveness of proven drugswhile minimizing risk by capitalizing on their known safety, efficacy andcommercialization history. The Company has several proprietary productcandidates in clinical development that address large market opportunities,including its two most advanced product candidates, a proprietary formulationof nebulized budesonide for the potential treatment of children with asthma,and a proprietary formulation of inhaled dihydroergotamine for the potentialtreatment of migraine, as well as a proprietary combination of an inhaledcorticosteroid and a long-acting beta2-agonist for the potential treatment ofasthma and chronic obstructive pulmonary disease. Additional information aboutMAP Pharmaceuticals can be found at http://www.mappharma.com.Lazard Capital Markets Fourth Annual Healthcare Conference Wednesday, November 28, 2007 2:30 pm, Eastern Time RBC Capital Markets 2007 Healthcare Conference Wednesday, December 12, 2007 12:30 pm, Eastern Time
SOURCE MAP Pharmaceuticals, Inc.